Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Liabilities and Shareholders Equity (2017 - 2025)

Inmune Bio's Liabilities and Shareholders Equity history spans 9 years, with the latest figure at $33.4 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 36.8% year-over-year to $33.4 million; the TTM value through Sep 2025 reached $148.4 million, down 29.02%, while the annual FY2024 figure was $39.6 million, 30.59% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $33.4 million at Inmune Bio, down from $37.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $107.7 million in Q3 2021 and bottomed at $33.4 million in Q3 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $62.7 million (2023), against an average of $65.6 million.
  • The largest annual shift saw Liabilities and Shareholders Equity soared 178.21% in 2021 before it plummeted 36.8% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $99.9 million in 2021, then decreased by 18.16% to $81.8 million in 2022, then plummeted by 30.31% to $57.0 million in 2023, then crashed by 30.59% to $39.6 million in 2024, then decreased by 15.68% to $33.4 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's Liabilities and Shareholders Equity are $33.4 million (Q3 2025), $37.7 million (Q2 2025), and $37.8 million (Q1 2025).